Literature DB >> 18704097

Augmentation of morphine-induced sensitization but reduction in morphine tolerance and reward in delta-opioid receptor knockout mice.

V I Chefer1, T S Shippenberg.   

Abstract

Studies in experimental animals have shown that individuals exhibiting enhanced sensitivity to the locomotor-activating and rewarding properties of drugs of abuse are at increased risk for the development of compulsive drug-seeking behavior. The purpose of the present study was to assess the effect of constitutive deletion of delta-opioid receptors (DOPr) on the rewarding properties of morphine as well as on the development of sensitization and tolerance to the locomotor-activating effects of morphine. Locomotor activity testing revealed that mice lacking DOPr exhibit an augmentation of context-dependent sensitization following repeated, alternate injections of morphine (20 mg/kg; s.c.; 5 days). In contrast, the development of tolerance to the locomotor-activating effects of morphine following chronic morphine administration (morphine pellet: 25 mg: 3 days) is reduced relative to WT mice. The conditioned rewarding effects of morphine were reduced significantly in DOPrKO mice as compared to WT controls. Similar findings were obtained in response to pharmacological inactivation of DOPr in WT mice, indicating that observed effects are not due to developmental adaptations that occur as a consequence of constitutive deletion of DOPr. Together, these findings indicate that the endogenous DOPr system is recruited in response to both repeated and chronic morphine administration and that this recruitment serves an essential function in the development of tolerance, behavioral sensitization, and the conditioning of opiate reward. Importantly, they demonstrate that DOPr has a distinct role in the development of each of these drug-induced adaptations. The anti-rewarding and tolerance-reducing properties of DOPr antagonists may offer new opportunities for the treatment and prevention of opioid dependence as well as for the development of effective analgesics with reduced abuse liability.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18704097      PMCID: PMC2639630          DOI: 10.1038/npp.2008.128

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  54 in total

1.  Neural substrate of sensitization to psychostimulants.

Authors:  P W Kalivas
Journal:  Clin Neuropharmacol       Date:  1992       Impact factor: 1.592

2.  Selective blockage of delta opioid receptors prevents the development of morphine tolerance and dependence in mice.

Authors:  E E Abdelhamid; M Sultana; P S Portoghese; A E Takemori
Journal:  J Pharmacol Exp Ther       Date:  1991-07-01       Impact factor: 4.030

3.  Naltrindole, a highly selective and potent non-peptide delta opioid receptor antagonist.

Authors:  P S Portoghese; M Sultana; A E Takemori
Journal:  Eur J Pharmacol       Date:  1988-01-27       Impact factor: 4.432

4.  Genetic differences in the rewarding and activating effects of morphine and ethanol.

Authors:  C L Cunningham; D R Niehus; D H Malott; L K Prather
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

5.  Delta opioid antagonist activity and binding studies of regioisomeric isothiocyanate derivatives of naltrindole: evidence for delta receptor subtypes.

Authors:  P S Portoghese; M Sultana; W L Nelson; P Klein; A E Takemori
Journal:  J Med Chem       Date:  1992-10-30       Impact factor: 7.446

6.  Modulation of morphine-induced sensitization by endogenous kappa opioid systems in the rat.

Authors:  R Spanagel; T S Shippenberg
Journal:  Neurosci Lett       Date:  1993-04-30       Impact factor: 3.046

7.  Evidence for delta opioid receptor subtypes in rat spinal cord: studies with intrathecal naltriben, cyclic[D-Pen2, D-Pen5] enkephalin and [D-Ala2, Glu4]deltorphin.

Authors:  P E Stewart; D L Hammond
Journal:  J Pharmacol Exp Ther       Date:  1993-08       Impact factor: 4.030

8.  Involvement of delta 2 opioid receptors in acute dependence on morphine in mice.

Authors:  Y Miyamoto; P S Portoghese; A E Takemori
Journal:  J Pharmacol Exp Ther       Date:  1993-06       Impact factor: 4.030

9.  Opioid agonist activity of ICI 174864 and its carboxypeptidase degradation product, LY281217.

Authors:  M L Cohen; R T Shuman; J J Osborne; P D Gesellchen
Journal:  J Pharmacol Exp Ther       Date:  1986-09       Impact factor: 4.030

Review 10.  An emerging role for the delta opioid receptor in the regulation of mu opioid receptor function.

Authors:  Raphael Rozenfeld; Noura S Abul-Husn; Ivone Gomez; Lakshmi A Devi
Journal:  ScientificWorldJournal       Date:  2007-11-02
View more
  46 in total

1.  How to design an opioid drug that causes reduced tolerance and dependence.

Authors:  Amy Chang Berger; Jennifer L Whistler
Journal:  Ann Neurol       Date:  2010-05       Impact factor: 10.422

2.  Development and in vitro characterization of a novel bifunctional μ-agonist/δ-antagonist opioid tetrapeptide.

Authors:  Lauren C Purington; Katarzyna Sobczyk-Kojiro; Irina D Pogozheva; John R Traynor; Henry I Mosberg
Journal:  ACS Chem Biol       Date:  2011-10-11       Impact factor: 5.100

3.  HIV-1 Tat and opioids act independently to limit antiretroviral brain concentrations and reduce blood-brain barrier integrity.

Authors:  Crystal R Leibrand; Jason J Paris; Austin M Jones; Quamrun N Masuda; Matthew S Halquist; Woong-Ki Kim; Pamela E Knapp; Angela D M Kashuba; Kurt F Hauser; MaryPeace McRae
Journal:  J Neurovirol       Date:  2019-05-17       Impact factor: 2.643

4.  Upregulation of nerve growth factor in central amygdala increases sensitivity to opioid reward.

Authors:  Bihua Bie; Yan Wang; You-Qing Cai; Zhi Zhang; Yuan-Yuan Hou; Zhizhong Z Pan
Journal:  Neuropsychopharmacology       Date:  2012-08-08       Impact factor: 7.853

5.  Delta-opioid receptor antagonists prevent sensitization to the conditioned rewarding effects of morphine.

Authors:  Toni S Shippenberg; Vladimir I Chefer; Alexis C Thompson
Journal:  Biol Psychiatry       Date:  2008-10-31       Impact factor: 13.382

6.  Tuned-Affinity Bivalent Ligands for the Characterization of Opioid Receptor Heteromers.

Authors:  Jessica H Harvey; Darcie H Long; Pamela M England; Jennifer L Whistler
Journal:  ACS Med Chem Lett       Date:  2012-08-09       Impact factor: 4.345

7.  Pentapeptides displaying mu opioid receptor agonist and delta opioid receptor partial agonist/antagonist properties.

Authors:  Lauren C Purington; Irina D Pogozheva; John R Traynor; Henry I Mosberg
Journal:  J Med Chem       Date:  2009-12-10       Impact factor: 7.446

Review 8.  Reward processing by the opioid system in the brain.

Authors:  Julie Le Merrer; Jérôme A J Becker; Katia Befort; Brigitte L Kieffer
Journal:  Physiol Rev       Date:  2009-10       Impact factor: 37.312

9.  Synthesis, modeling, and pharmacological evaluation of UMB 425, a mixed μ agonist/δ antagonist opioid analgesic with reduced tolerance liabilities.

Authors:  Jason R Healy; Padmavani Bezawada; Jihyun Shim; Jace W Jones; Maureen A Kane; Alexander D MacKerell; Andrew Coop; Rae R Matsumoto
Journal:  ACS Chem Neurosci       Date:  2013-06-11       Impact factor: 4.418

10.  Effect of Sinomenine on the Morphine-Dependence and Related Neural Mechanisms in Mice.

Authors:  Miao Fang; Junkui Li; Daoqi Zhu; Chaohua Luo; Chan Li; Chen Zhu; Menglin Fan; Ken Kin-Lam Yung; Zhixian Mo
Journal:  Neurochem Res       Date:  2017-11-08       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.